Literature DB >> 10517195

Mycobacterium malmoense infections in immunocompetent patients.

R Enzensberger1, K P Hunfeld, M Krause, S Rüsch-Gerdes, V Brade, B Böddinghaus.   

Abstract

While Mycobacterium malmoense infections were originally restricted to northern Europe, there has been an increasing number of reports of cases of infection in other countries. Two cases of infections due to Mycobacterium malmoense in immunocompetent patients in Germany are presented. In both cases a presumptive diagnosis of tuberculosis was established initially. Mycobacterium malmoense was cultured after a long incubation period (6-8 weeks). The patients were successfully treated with a triple regimen consisting of rifampicin, ethambutol and clarithromycin. The epidemiology and difficulties in diagnosis of Mycobacterium malmoense infection are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517195     DOI: 10.1007/s100960050350

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Pulmonary Infection Due to Mycobacterium malmoense in a Patient with Crohn Disease.

Authors:  Cory D Cowan; John J Hawboldt; Mazen Bader
Journal:  Can J Hosp Pharm       Date:  2009-11

2.  Differential requirement for interferon-gamma to restrict the growth of or eliminate some recently identified species of nontuberculous mycobacteria in vivo.

Authors:  S Ehlers; E Richter
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

3.  Mycobacterium malmoense lymphadenitis in Spain: first two cases in immunocompetent patients.

Authors:  A I López-Calleja; M A Lezcano; S Samper; F de Juan; M J Revillo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-26       Impact factor: 3.267

Review 4.  An association between Mycobacterium malmoense and coal workers' pneumoconiosis.

Authors:  Emmet E McGrath; Philip Bardsley
Journal:  Lung       Date:  2008-08-30       Impact factor: 2.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.